APLS
Price
$19.59
Change
-$0.50 (-2.49%)
Updated
Jul 25 closing price
Capitalization
2.46B
5 days until earnings call
IGMS
Price
$1.27
Change
-$0.01 (-0.78%)
Updated
Jul 25 closing price
Capitalization
76.44M
16 days until earnings call
Interact to see
Advertisement

APLS vs IGMS

Header iconAPLS vs IGMS Comparison
Open Charts APLS vs IGMSBanner chart's image
Apellis Pharmaceuticals
Price$19.59
Change-$0.50 (-2.49%)
Volume$2.94M
Capitalization2.46B
IGM Biosciences
Price$1.27
Change-$0.01 (-0.78%)
Volume$108.76K
Capitalization76.44M
APLS vs IGMS Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IGMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. IGMS commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and IGMS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (APLS: $19.59 vs. IGMS: $1.27)
Brand notoriety: APLS and IGMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 119% vs. IGMS: 17%
Market capitalization -- APLS: $2.46B vs. IGMS: $76.44M
APLS [@Biotechnology] is valued at $2.46B. IGMS’s [@Biotechnology] market capitalization is $76.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileIGMS’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • IGMS’s FA Score: 0 green, 5 red.
According to our system of comparison, both APLS and IGMS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 6 TA indicator(s) are bullish while IGMS’s TA Score has 4 bullish TA indicator(s).

  • APLS’s TA Score: 6 bullish, 3 bearish.
  • IGMS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, APLS is a better buy in the short-term than IGMS.

Price Growth

APLS (@Biotechnology) experienced а +0.62% price change this week, while IGMS (@Biotechnology) price change was -0.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

APLS is expected to report earnings on Nov 10, 2025.

IGMS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.46B) has a higher market cap than IGMS($76.4M). APLS YTD gains are higher at: -38.609 vs. IGMS (-79.214). APLS (-176.08M) and IGMS (-178.4M) have comparable annual earnings (EBITDA) . APLS has more cash in the bank: 358M vs. IGMS (152M). IGMS has less debt than APLS: IGMS (44M) vs APLS (470M). APLS has higher revenues than IGMS: APLS (776M) vs IGMS (2.68M).
APLSIGMSAPLS / IGMS
Capitalization2.46B76.4M3,223%
EBITDA-176.08M-178.4M99%
Gain YTD-38.609-79.21449%
P/E RatioN/AN/A-
Revenue776M2.68M28,944%
Total Cash358M152M236%
Total Debt470M44M1,068%
FUNDAMENTALS RATINGS
APLS vs IGMS: Fundamental Ratings
APLS
IGMS
OUTLOOK RATING
1..100
1328
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6264
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (70) in the Medical Distributors industry is in the same range as IGMS (93) in the null industry. This means that APLS’s stock grew similarly to IGMS’s over the last 12 months.

APLS's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as IGMS (100) in the null industry. This means that APLS’s stock grew similarly to IGMS’s over the last 12 months.

APLS's SMR Rating (98) in the Medical Distributors industry is in the same range as IGMS (100) in the null industry. This means that APLS’s stock grew similarly to IGMS’s over the last 12 months.

APLS's Price Growth Rating (62) in the Medical Distributors industry is in the same range as IGMS (64) in the null industry. This means that APLS’s stock grew similarly to IGMS’s over the last 12 months.

APLS's P/E Growth Rating (100) in the Medical Distributors industry is in the same range as IGMS (100) in the null industry. This means that APLS’s stock grew similarly to IGMS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSIGMS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 17 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IGMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SDGCX91.41N/A
N/A
DWS Capital Growth C
KDHIX54.24N/A
N/A
DWS CROCI Equity Dividend Inst
AQLGX17.58N/A
N/A
Alta Quality Growth Institutional
DVRPX17.63N/A
N/A
UBS US Dividend Ruler P2
FEORX30.05-0.02
-0.07%
First Eagle Overseas R6

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-2.49%
ROIV - APLS
48%
Loosely correlated
+1.49%
DNLI - APLS
46%
Loosely correlated
-4.47%
EYPT - APLS
45%
Loosely correlated
-0.10%
BPMC - APLS
43%
Loosely correlated
N/A
KYMR - APLS
43%
Loosely correlated
-0.13%
More

IGMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IGMS has been loosely correlated with MRSN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IGMS jumps, then MRSN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGMS
1D Price
Change %
IGMS100%
-0.78%
MRSN - IGMS
53%
Loosely correlated
-4.38%
CRNX - IGMS
47%
Loosely correlated
+1.91%
DYN - IGMS
46%
Loosely correlated
+7.68%
MDGL - IGMS
42%
Loosely correlated
-0.26%
APLS - IGMS
40%
Loosely correlated
-2.49%
More